Download is designed to stimulate the body`s immune system to target and

ONCOSEC
is designed to stimulate the body’s immune
system to target and eliminate cancerous cells.
BENEFITS
Administered in an outpatient setting
Delivers DNA-based therapeutics directly into tumors
Can be combined with other therapeutic approaches
Empowers immune system to target and eliminate cancer
Potential to trigger a systemic response that reaches
cancerous cells beyond the treatment area
www.OncoSec.com
Email — [email protected]
Cancer cells
surrounded by
healthy cells.
4
During brief electroporation
DNA IL-12 enters the cell and
induces production of IL-12.
3
2
1
DNA IL-12
(a gene-based
immune trigger)
is injected into tumor.
Electroporation opens
microscopic pores
in cell membranes, allowing
the agent to enter.
6
5
IL-12 is produced, eliciting
an anti-cancer immune
response.
Cancerous cells are detected
as a result of the immune
response. These cells are
targeted for destruction.
7
Studies to date have
shown a systemic response
(reduction in untreated
tumors)
METASTATIC MELANOMA STUDY | DNA IL-12
MOFFITT CANCER CENTER
— 24 Patients
1st human study using electro-gene therapy
76%
of lesions
showed >20%
necrosis
42%
disease
control
rate*
13%
of patients
showed complete
remission
*includes stable disease, partial response and complete response
P HA S E I — ME L A NO MA DATA
P HA S E I I — I N T E R I M ME L A NO MA DATA
50%
31%
14%
systemic
response
best overall
response rate
complete
remission
MULTI-CENTER
— 28 Patients
A total of 52 patients (Phase I & Phase II) have been treated to date
without a single, drug-related serious adverse event.
EXCHANGE/SYMBOL: OTCQB : ONCS
A N A LY S T C O V E R A G E
NOBLE FINANCIAL
MAXIM GROUP
H.C. WAINRIGHT
SCAN THE CODE
to download our complete Investor Overview
Telephone —
+1 855 662 6732
Email —
[email protected]
Website —
www.OncoSec.com
Address —
OncoSec Headquarters
9810 Summers Ridge Road
Suite 110
San Diego
California
92121